Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption
17 nov. 2014 08h40 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Nov 17, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat...
Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update
07 nov. 2014 11h55 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Nov 7, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate...
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels
03 nov. 2014 07h59 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Nov 3, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to manage post meal...
Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients With Type 2 Diabetes
09 oct. 2014 08h38 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Oct 9, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to manage post meal...
Boston Therapeutics Appoints David S.H. Bell, MB, FACP, FACE to Its Medical Advisory Board
08 oct. 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Oct 8, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics designed to treat...
Boston Therapeutics Files Patent Application for Novel Therapeutic Uses of BTI-320
07 oct. 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Oct 7, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat...
Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors
01 oct. 2014 13h46 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Oct 1, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and...
Benchworks Collaborates With Boston Therapeutics to Market sugardown(R)
29 sept. 2014 07h00 HE
|
Boston Therapeutics
CHESTERTOWN, MD--(Marketwired - Sep 29, 2014) - Benchworks is pleased to announce the launch of the commercial phase of sugardown®, a dietary supplement developed by Boston Therapeutics, Inc....
Boston Therapeutics Appoints Meng Hee Tan, M.D. to Consulting Medical Director
23 sept. 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Sep 23, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center for Phase III Study of BTI-320
22 sept. 2014 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Sep 22, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes,...